NRD
VRDN icon

Nebula Research & Development’s Viridian Therapeutics VRDN Stock Holding History

Nebula Research & Development’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,531
Closed -$169K – 1168
2025
Q1 		$169K Sell
12,531
-4,601
-27% -$78.4K 0.02% 880
2024
Q4 		$328K Buy
+17,132
New +$373K 0.04% 689
2024
Q3 		– Sell
-18,897
Closed -$246K – 1182
2024
Q2 		$246K Buy
+18,897
New +$262K 0.04% 671

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Nebula Research & Development's VRDN Position: Q2 2025 in Review

Nebula Research & Development sold out of Viridian Therapeutics (VRDN) in Q2 2025, closing a stake of 12,531 shares — an estimated $169K sold.

Nebula Research & Development first reported a position in VRDN in Q2 2024 and held it in 3 quarters. The position peaked at $328K in Q4 2024. 170 funds tracked by Wall St. Rank hold VRDN as of Q2 2025.

  • Nebula Research & Development reported no remaining Viridian Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 12,531 Viridian Therapeutics shares in Q2 2025, an estimated $169K.
  • Nebula Research & Development first reported a position in Viridian Therapeutics in Q2 2024 and held it in 3 quarters.
  • Nebula Research & Development's Viridian Therapeutics position peaked at $328K in Q4 2024.
  • 170 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.